Physician profile
Grayson Christopher Eubanks
NPI 1932635679
$913.40
in general payments reported to CMS, 2019-2025
16 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2023: $253 · 2024: $168 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $145.21 | 2023 | Zio Xt Patch |
| Heartflow, INC. | $129.67 | 2025 | |
| Boston Scientific Corporation | $111.81 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.85 | 2023-2025 | Lifevest |
| Janssen Biotech, INC. | $74.49 | 2025 | Simponi Aria, Stelara, Tremfya |
| Novo Nordisk INC | $62.83 | 2023-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $46.91 | 2024 | |
| Exact Sciences Corporation | $38.60 | 2023-2024 | Cologuard Collection Kit |
| Recor Medical INC | $35.37 | 2025 | Paradise Ultrasound Renal Denervation System |
| Amgen INC. | $35.33 | 2024-2025 | Repatha, Repatha |
| Madrigal Pharmaceuticals | $31.10 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $30.19 | 2024-2025 | Dificid, Verquvo |
| Astrazeneca Pharmaceuticals Lp | $25.27 | 2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $22.53 | 2025 | Camzyos |
| Grifols USA, LLC | $21.21 | 2025 | Prolastin-C Liquid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $21.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grayson Eubanks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.